Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era

RECOMMENDED

Lung Cancer

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

★ 1 Recommended by Prof. Dr Stephan Bodis, Faculty Member

★ 2 Recommended by Alexander Meisel, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Oncol.

Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ

doi: 10.1016/S1470-2045(19)30519-4.

RECOMMENDED

Lung Cancer

Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Zhou N, Velez MA, Bachrach B, Gukasyan J, Fares CM, Cummings AL, Lind-Lebuffe JP, Akingbemi WO, Li DY, Brodrick PM, Yessuf NM, Rettinger S, Grogan T, Rochigneux P, Goldman JW, Garon EB, Lisberg A

doi: 10.1016/j.lungcan.2021.08.009

RECOMMENDED

Lung Cancer

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lung Cancer

Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JC, Bajars M, Ruisi M, Manitz J, Barlesi F

doi: 10.1016/j.lungcan.2021.01.026

Lung Cancer

Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Cytryn S, Ferreira V, Boland P, Chachoua A, Sabari J

doi: 10.1016/j.lungcan.2021.05.033

RECOMMENDED

Lung Cancer

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Ther Adv Respir Dis.

Botticella A, Mezquita L, Le Pechoux C, Planchard D

doi: 10.1177/1753466619885530.

RECOMMENDED

Lung CancerPleural DiseasesFurther Publications

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

Chest.

Suresh K, Naidoo J, Lin CT, Danoff S

doi: 10.1016/

RECOMMENDED

Lung Cancer

Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Andreano A, Bergamaschi W, Russo AG

doi: 10.1016/j.lungcan.2021.06.019

RECOMMENDED

Lung Cancer

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer.

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC

doi: 10.1016/j.lungcan.2020.10.006.Visit the original publication at ncbi.nlm.nih.gov

RECOMMENDED

Lung Cancer

Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)

★ 1 Recommended by Dr Martin Frey, Faculty Member

Lung Cancer

Tufman A, Neumann J, Manapov F, Sellmer L, Jung A, Kauffmann-Guerrero D, Kahnert K, Mertsch P, Borgmeier A, Semrau S, Rittmeyer A, Ulm B, Ulm K, Flentje M, Fietkau R, Huber RM

doi: 10.1016/j.lungcan.2021.07.008

Related content

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)